Filing Flows › ResMed (RMD) › How it makes money
How ResMed (RMD) makes money
ResMed (RMD) made $1.4B of revenue in the first quarter fiscal 2027 (Q1 FY27), +6% from a year earlier. Total Sleep and Breathing Health brought in $1.3B (89%); Residential Care Software brought in $155M (11%). Of every dollar of revenue, 62¢ was left as gross profit, 32¢ was left as operating profit, 30¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q1 FY27
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Total Sleep and Breathing Health | $1.3B | 89.0% | -2% | +8% |
| Residential Care Software | $155M | 11.0% | -10% | -7% |
Where each dollar of revenue goes
| Line | Q1 FY27 | % of revenue |
|---|---|---|
| Revenue | $1.4B | 100.0% |
| Cost of revenue | $544M | 38.5% |
| Gross profit | $871M | 61.5% |
| Operating expenses | $418M | 29.5% |
| Operating profit | $453M | 32.0% |
| Income tax | $121M | 8.5% |
| Net earnings | $418M | 29.6% |
| Operating cash flow | $422M | 29.9% |
| Free cash flow | $374M | 26.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q1 FY27 | $1.4B | +6% |
| Q4 FY26 | $1.5B | +9% |
| Q3 FY26 | $1.4B | +11% |
| Q2 FY26 | $1.4B | +11% |
| Q1 FY26 | $1.3B | +9% |
| Q4 FY25 | $1.3B | +10% |
| Q3 FY25 | $1.3B | +8% |
From ResMed's 10-Q filed Oct 30, 2026 (on EDGAR).
Questions
How does ResMed make money?
ResMed (RMD) made $1.4B of revenue in the first quarter fiscal 2027 (Q1 FY27), +6% from a year earlier. Total Sleep and Breathing Health brought in $1.3B (89%); Residential Care Software brought in $155M (11%). Of every dollar of revenue, 62¢ was left as gross profit, 32¢ was left as operating profit, 30¢ was left as net earnings.
What is ResMed's biggest business?
Total Sleep and Breathing Health: $1.3B in the first quarter fiscal 2027, 89% of revenue, +8% from a year earlier.
What is ResMed's profit margin?
Net earnings were $418M, 29.6% of revenue, in the first quarter fiscal 2027; the operating margin was 32.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.